Abstract
Malaria is a devastating human parasitic disease that receives enhanced attention due to the emergence of resistance to traditional drugs. Thus, the search for new molecular targets is a major goal. PfAM1 is an aminopeptidase from Plasmodium falciparum, William H. Welch 1897, belonging to the M1 family of metalloproteases, which is a promising target of inhibitors to block the intra-erythrocytic stages of the parasite. Since its identification in 1998, many efforts have been done to validate PfAM1 as an appropriate target of antimalarials. The present work is a critical review of the main structural, functional and kinetic characteristics of PfAM1, as well as a summary of the effects of key inhibitors at molecular and cellular levels. The systematization of experimental results should contribute to a better understanding of the properties of PfAM1 as a target of antimalarials and promote research projects focused on the development of PfAM1 inhibitors.
Keywords: Antimalarials, growth inhibition, M1 family, metallo-aminopeptidases, Plasmodium falciparum, protease inhibitors.
Current Drug Targets
Title:Plasmodium falciparum M1-Aminopeptidase: A Promising Target for the Development of Antimalarials
Volume: 15 Issue: 12
Author(s): Jorge Gonzalez-Bacerio, Rafael Fando, Alberto del Monte-Martinez, Jean-Louis Charli and Maria de los A. Chávez
Affiliation:
Keywords: Antimalarials, growth inhibition, M1 family, metallo-aminopeptidases, Plasmodium falciparum, protease inhibitors.
Abstract: Malaria is a devastating human parasitic disease that receives enhanced attention due to the emergence of resistance to traditional drugs. Thus, the search for new molecular targets is a major goal. PfAM1 is an aminopeptidase from Plasmodium falciparum, William H. Welch 1897, belonging to the M1 family of metalloproteases, which is a promising target of inhibitors to block the intra-erythrocytic stages of the parasite. Since its identification in 1998, many efforts have been done to validate PfAM1 as an appropriate target of antimalarials. The present work is a critical review of the main structural, functional and kinetic characteristics of PfAM1, as well as a summary of the effects of key inhibitors at molecular and cellular levels. The systematization of experimental results should contribute to a better understanding of the properties of PfAM1 as a target of antimalarials and promote research projects focused on the development of PfAM1 inhibitors.
Export Options
About this article
Cite this article as:
Gonzalez-Bacerio Jorge, Fando Rafael, Monte-Martinez del Alberto, Charli Jean-Louis and Chávez de los A. Maria, Plasmodium falciparum M1-Aminopeptidase: A Promising Target for the Development of Antimalarials, Current Drug Targets 2014; 15 (12) . https://dx.doi.org/10.2174/1389450115666141024115641
DOI https://dx.doi.org/10.2174/1389450115666141024115641 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Physiologic Activity and Mechanism of Quercetin-Like Natural Plant Flavonoids
Current Pharmaceutical Biotechnology Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy Eating Disorders in the Time of the COVID-19 Pandemic: A Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Homeostasis and Compensatory Homeostasis: Bridging Western Medicine and Traditional Chinese Medicine
Current Cardiology Reviews Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Current Medicinal Chemistry Proteochemometrics for the Prediction of Binding to the MHC Proteins
Letters in Drug Design & Discovery The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Syntheses and Biological Activities of triazole-based Sulfonamides
Current Organic Chemistry Effects of Dietary L-arginine Supplementation from Conception to Post- Weaning in Piglets
Current Protein & Peptide Science Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Association Between Vitamin D Serum Level and Depression
Current Psychopharmacology Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Proteomic Approaches to Study the Pig Intestinal System
Current Protein & Peptide Science Editorial [Hot Topic: Angiogenesis in Tumor Growth and Metastasis (Executive Editor: Riichiro Abe)]
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science A Mini Review on Biological Activities of Pyridazinone Derivatives as Antiulcer, Antisecretory, antihistamine and Particularly Against Histamine H3R
Mini-Reviews in Medicinal Chemistry Inflammatory Mechanisms and Oxidative Stress in Peyronies Disease: Therapeutic “Rationale” and Related Emerging Treatment Strategies
Inflammation & Allergy - Drug Targets (Discontinued)